Johnson & Johnson（JNJ） · Pharmaceuticals

Johnson & Johnson Deep Value Analysis: A Good Company Is Not Cheap

May 25, 2026·~23 min read

Quick ReadPlain-language overview · read this first

After Johnson & Johnson separated its consumer health business, it is now driven solely by prescription drugs and medical devices. Sales were 94.2 billion dollars in 2025, with free cash flow of 19.7 billion. The rating is Watch: a good company at a bad price.

The issue is not the business, but the odds. A 234 dollars share price implies a free cash flow yield of only 3.4%, below both the 10-year Treasury yield of 4.57% and the Aaa corporate bond yield of 5.64%, so new buyers' cash return cannot beat the risk-free rate. Based on a DCF using 20 billion of normalized owner earnings, conservative, base, and optimistic intrinsic value estimates are 120/165/230 dollars. The current price is sitting at the upper edge of the optimistic case. STELARA has entered the biosimilar phase, OPSUMIT faces generics in 2026, and DARZALEX, which accounts for 15% of revenue, has its core U.S. patent expiring in 2029. New platforms have to carry the handoff for growth to hold up.

Capital allocation also loses points: net debt was already 32.9 billion in Q1 2026, yet the company still repurchased 4.0 billion at a not-cheap 234 dollars valuation and increased net debt by 7.2 billion. Add the still-unresolved tail risk from 75,000 talc plaintiffs, and the ideal buying range is 160-185 dollars. Any downside trigger could lead to a 40%-50% drawdown.

Lead
JNJ is an understandable healthcare leader with a deep moat and stable free cash flow. The core view is that the stock price of $234 is already close to the upper end of the model's optimistic case, while its 3.4% cash return is below the 10-year Treasury yield of 4.57%, so new buyers should wait. Research rating Watch: a high-quality compounder, but the margin of safety is not sufficient at the current price.

Full report

Prices in the article are as of publication; see the valuation band above for the live price.

Conclusion First

Investment rating: Watch. If Johnson & Johnson is viewed as an asset to hold for the long term, even as if one were "acquiring a business," it remains a high-quality, understandable healthcare leader with strong cash flow and a deep moat. But a high-quality company does not automatically make a high-return investment. As of May 22, 2026, JNJ traded at about $234.34, with a market capitalization of about $573 billion and a trailing twelve-month P/E of about 27.2x. The company generated about $19.7 billion of free cash flow in 2025, implying a free cash flow yield of only about 3.4%, below the contemporaneous 10-year Treasury yield of about 4.57% and Moody's Aaa corporate bond yield of about 5.64%. That means investors buying JNJ today are not paying a "cheap" price. They are paying for a quality premium, management's reinvestment execution, and continued pipeline success.

Core judgment. First, this is an understandable business. Today's JNJ no longer includes the consumer health business. Its core consists of two segments, Innovative Medicine and MedTech, with 2025 revenue of about $60.4 billion and $33.8 billion, respectively. Second, it remains a good business. In 2025, the company generated $94.2 billion in sales, $24.5 billion in operating cash flow, and about $19.7 billion in free cash flow. The company also disclosed global sales CAGRs of about 6.7% and 5.2% over the past five and ten years, respectively. Third, the moat is real, but not impregnable. Patents, regulation, brand, channels, scale, and physician switching costs are all strong, but STELARA has entered the biosimilar pressure period, OPSUMIT also faces generic pressure, and DARZALEX is highly important to revenue while requiring large royalty-sharing payments to Genmab. Fourth, management is broadly credible, but capital allocation over the past two years has not been perfect. High-priced acquisitions, rising debt, and sizable buybacks while valuation was not low have weakened the margin of safety for new buyers.

Is there a margin of safety at the current price: not obvious. Using a conservative owner-earnings valuation, I estimate intrinsic value in a broad range of roughly $120 to $230 per share, while the more reasonable neutral range is closer to $150 to $190 per share. This means the current price is close to the upper end of the optimistic case in my model. For an investor who is balanced but conservative and expects to hold for more than 10 years, the margin of safety is not thick enough.

Suitable investor type. JNJ is better suited to long-term value investors who already understand healthcare, are willing to track pipeline and litigation developments over time, and can accept an "excellent company, not necessarily cheap" setup. It is less suitable for new buyers seeking a high-conviction, high-return entry at the current price. For existing holders, it looks more like an asset that can continue to be held but does not demand urgent heavy additions. For new capital, it looks more like a name to place on a core watchlist while waiting for better odds from either price or fundamentals.

Largest uncertainties. The three most important uncertainties are: first, although the present value of the company's current reserve for talc litigation is about $3.4 billion, as of March 29, 2026 there were still about 75,000 U.S. claimants, so tail losses are not fully capped; second, whether declines in mature products such as STELARA/OPSUMIT can continue to be offset by new and existing growth platforms such as TREMFYA, DARZALEX, CARVYKTI, SPRAVATO, CAPLYTA, RYBREVANT/LAZCLUZE; third, management's capital allocation over the next two to three years, especially whether high-priced acquisitions and debt-supported buybacks will erode intrinsic value per share.

Business Understanding and Industry Structure

How this company makes money. JNJ's current business structure is clear. One side is Innovative Medicine, which mainly sells prescription drugs in oncology, immunology, neuroscience, pulmonary arterial hypertension, infectious diseases, and cardiovascular/metabolic diseases. The other side is MedTech, covering medical devices and related consumables in surgery, orthopedics, cardiovascular care, ophthalmology, and other areas. In 2025, total company sales were about $94.2 billion, including about $60.4 billion from Innovative Medicine and about $33.8 billion from MedTech. Customers are not ordinary end consumers. The business is more B2B/B2H, involving wholesalers, distributors, retail outlets, hospitals, surgical centers, physicians, and other healthcare professionals. The revenue model is essentially "selling drugs + selling devices + selling consumables + selling supporting solutions," although the pharmaceutical side must deduct large discounts, rebates, and payer-related adjustments.

The business has strong overall repeatability and predictability, but it is not free of cycles. On the drug side, repeatability comes from long-term treatment for chronic disease and oncology, plus market expansion. On the device side, repeatability comes from consumables, contact lenses, rising procedure penetration, and mature product iteration. The company disclosed that new products launched over the past five years contributed about 25% of 2025 sales, showing that JNJ is not a company "living off old products." It is a healthcare innovation platform that must keep reinvesting, launching new products, and passing regulatory reviews. The model is sustainable, but it requires management to keep proving R&D and acquisition efficiency.

In cost structure, JNJ is not a low-capex, pure software-like company, but it is far from an asset-heavy trap. In 2025, gross profit was about $63.9 billion, with a gross margin close to 68%. Full-year R&D spending was about $14.67 billion, or about 15.6% of sales. Capital expenditure was about $4.83 billion. This shows that the company's "core costs" are not steel-mill depreciation, but R&D, clinical development, registration, sales, and compliance systems. For this kind of company, the most important question is not single-year profit. It is whether R&D converts into new products and new indications, whether acquisitions fill product cliffs, and whether cash flow can steadily cover shareholder distributions and debt.

The business is not completely dispersed either. In channels, three wholesalers each accounted for about 21.8%, 15.5%, and 11.1% of gross revenue in 2025. In products, DARZALEX/DARZALEX FASPRO accounted for about 15% of total company revenue in 2025, while JNJ also needs to pay Genmab about 12% to 20% of sales as royalties. Related core patents run in the U.S. roughly to 2029 and in parts of Europe to 2031/2032. In other words, JNJ is already diversified, but it still has three practical issues that require long-term monitoring: channel concentration, large-product concentration, and patent duration.

Can I understand this business? At a high level, I think yes. This is a company that commercializes complex medical innovation through R&D, regulatory capability, global channels, physician relationships, and scaled manufacturing. The difficulty is not that the "business model is incomprehensible." The real difficulty is that product-level science and regulation are highly complex, especially on the drug side. If you cannot track patent schedules, indication expansion, competing drugs, and biosimilar timing over the long term, then you do not truly understand the company. On a scale of one to five, I give it 4/5: understandable at the enterprise level, not simple at the molecular level.

If the stock market closed for five years, would I be willing to hold it? If my purchase cost were reasonable enough, yes. Five years from now, society will still need oncology drugs, immunology drugs, cardiovascular devices, eye-care products, and surgical tools. JNJ has sufficiently deep R&D, regulatory, channel, and global capabilities, and it will not lose customers in the real world simply because the exchange is closed. The question is not "am I willing to own the business?" The question is "is today's price worth paying to become a business owner?" These two questions must be separated.

Industry and competitive structure. From the perspective of a long-term owner, JNJ operates in an industry with stable demand, innovation-driven returns, heavy regulation, high capital intensity, and concentrated profit pools. Demand is not weak. Aging populations, chronic disease, oncology, cardiovascular surgery, vision correction, and minimally invasive therapy all have long duration. But supply is not easy either. Drugs face patent cliffs, biosimilars, and payer constraints. Devices face hospital cost control, volume-based procurement, technological substitution, and physician learning curves. Put differently, this is not an industry that small companies can easily copy, but it is also not an industry where incumbents can lie back and collect interest.

There is no single perfect peer. On the drug side, JNJ can be compared with large pharmaceutical companies such as Merck and AbbVie. On the device side, it is better compared with Abbott, Medtronic, and Stryker. As of May 22, 2026, JNJ's trailing P/E was about 27.2x, higher than Abbott at about 24.5x and Medtronic at about 22.0x, but lower than Merck at about 34.5x and Stryker at about 36.6x. AbbVie at about 106x trailing P/E is clearly distorted by low GAAP EPS and has limited reference value. In terms of business mix, JNJ is distinctive because it combines pharmaceuticals and devices. Its volatility is often lower than that of pure-play pharmaceutical companies, but its growth may not be stronger than the best first-tier growth device companies. I therefore would not view it as "cheap growth." It is more like a high-quality defensive compounder.

JNJ's industry position remains strong. In investor materials, the company disclosed that more than 75% of sales come from categories ranked No. 1 or No. 2 in global market share. In 2025, the company also said it had 28 platforms with annual sales above $1 billion. My inference is that JNJ is closer to a "good company in a good industry" than to a "top student in a bad industry." Still, the industry's attractiveness is not perfect, because payer, regulatory, and patent cycles on the drug side naturally flatten part of the advantage. I rate industry attractiveness 4/5.

Moat Analysis

Brand advantage: yes, and stronger on the device side. On the drug side, the real moat is not consumer branding. It is physician trust, clinical data, labeled indications, and real-world prescribing habits. On the device side, brand, training systems, procedure ecosystems, and hospital relationships matter more. In 2025, the company's Vision business explicitly noted that contact lens growth came from market growth, the performance of the ACUVUE OASYS 1-Day series, and strategic pricing. That reflects the combination of brand, channel, and product strength.

Cost advantage: yes, but not cost leadership in the lowest-price sense. JNJ's advantage comes more from global procurement, scaled manufacturing, reuse of regulatory and compliance systems, and shared commercial platforms. It is not the kind of "absolute lowest cost" advantage seen in retail. In healthcare, the truly valuable "cost advantage" often shows up in customer acquisition cost, tolerance for failure, and reuse of R&D platforms. Large companies can absorb failed projects, launch globally faster, and spread fixed compliance and sales costs. The company spent $14.67 billion on R&D in 2025, and new products contributed 25% of sales. This scale and reuse capability itself is part of the cost advantage.

Scale advantage: very strong. The company generated $94.2 billion in sales in 2025 and $24.1 billion in sales in Q1 2026 alone. It also spans pharmaceuticals and devices, with obvious scale effects in cash flow, global channels, clinical systems, legal operations, and regulatory systems. More importantly, scale lets JNJ offset a single-product slowdown with a portfolio response. In 2025, the company explicitly noted that the decline in STELARA had a negative impact of about 6.2% on global operational sales, yet full-year sales still grew 6.0%. That shows portfolio resilience is real.

Network effects: basically none. This is not an internet platform. JNJ's advantages come from science, regulation, channels, and brand, not from network effects among users. I would clearly mark this as "no." That is actually good. We do not need to pretend every excellent company has network effects. If there are none, say there are none.

Switching costs: medium to high. This is especially clear on the device side. Once products in surgery, orthopedics, arrhythmia treatment, and other areas enter hospital systems, physician training systems, and operating workflows, replacement is not easy. In orthopedics, the company mentioned the pull-through effect from the ATTUNE platform and the VELYS robotic-assisted system. In cardiovascular, electrophysiology and Shockwave platforms also rely on procedure penetration and physician adoption. On the drug side, switching costs come more from clinical guidelines, physician habits, payer access, and patient adherence.

Channel advantage: yes. JNJ has global distribution capability, but channel concentration must also be recognized. Three wholesalers together account for close to half of gross revenue. This is not necessarily bad, but it means channel bargaining power and inventory management cannot be treated casually. The channel advantage exists, but it is not risk-free.

Patents, licenses, and regulatory barriers: very strong. This is one of JNJ's core moats. On the drug side, what really blocks competitors is patents, clinical data, regulatory filings, indication expansion capability, and payer access. On the device side, it is FDA/EMA approvals, manufacturing quality, clinical evidence, and physician training. In 2025, the company disclosed 51 approvals, 32 submissions, and the launch of 11 new Phase 3 programs. These are not short-term stock stories. They are the process by which the moat is reproduced.

Data advantage: limited, but supportive. JNJ does not live off a "user data network," but clinical trials, real-world evidence, drug safety data, and device-use data continue to reinforce its regulatory and commercialization capabilities. I view this as a secondary moat, not a primary one.

Corporate culture and operating capability: strong. JNJ's "Our Credo" cannot be directly discounted into cash, but it has some influence on compliance, long-termism, and organizational resilience. More importantly, over the past few years the company has managed the Kenvue separation, litigation, and patent pressure while completing Shockwave, Intra-Cellular, Halda, and other transactions, and still generated nearly $24.5 billion of operating cash flow in 2025. That shows its organizational operating capability remains strong.

Capital allocation ability: above average, but not flawless. In recent years the company has maintained dividends, and in 2026 it raised the dividend to $5.36 per share annually, achieving 64 consecutive years of dividend increases. It has also pursued major acquisitions such as Shockwave and Intra-Cellular. But I must be clear: capital allocation should not be judged by "whether management did something," but by "whether management did the right thing at a good price." Net debt had reached $27.8 billion by the end of 2025 and rose further to about $32.9 billion in Q1 2026. Yet in Q1 2026, the company still repurchased $4.0 billion of stock while adding about $7.2 billion of net new short- and long-term debt. From a long-term owner perspective, this is not the most ideal way to repurchase shares.

Is the moat widening, stable, or narrowing? My judgment: stable overall, narrowing locally on the drug side, widening locally on the device side. The narrowing on the drug side comes from patent durations and competitive pressure around STELARA, OPSUMIT, and eventually DARZALEX. The widening on the device side comes from high-growth platforms such as Shockwave, Abiomed, electrophysiology, and Vision, plus path dependence created by physician training and procedure penetration. The company is not strengthening in a straight line. It has a typical "portfolio renewal moat": old moats narrow, and new moats must connect. My overall score is 4/5.

Can it raise prices in inflation? Answer: yes, but mainly through innovation, mix, and selective pricing rather than broad hard price increases. The company disclosed that 2025 sales growth was broken down as follows: volume +8.4%, price contribution -3.1%, and foreign exchange +0.7%. This shows the company did not rely on broad price increases to drive growth overall. But in certain segments such as Vision, the company did mention strategic pricing actions. My conclusion is that JNJ's "pricing power" is real, but it is more like "implicit pricing power," attached to innovation, brand, and product upgrades, rather than simply raising the price list.

Management and Capital Allocation

On trustworthiness, I give management a cautious positive rating. The governance framework is generally standard. In 2025, the board held 14 meetings, and each incumbent director attended at least 75% of board and committee meetings. The company has a Lead Independent Director. Directors and executives have explicit stock ownership requirements. Pledging, hedging, and short-selling are prohibited. The company also has mandatory and discretionary clawback policies. For a mature blue-chip pharmaceutical company, these are the governance features it should have.

But if management is assessed as "business operators" rather than as a "governance sample," we need to look further. First, management is not an owner-type team. The 2026 proxy shows that all directors and executives together still own/control less than 1% of outstanding shares. CEO Joaquin Duato beneficially owns about 1.408 million shares, and the CEO must meet a stock ownership requirement equal to 12x annual salary, while other executives must meet 6x annual salary. Still, this is not the kind of ownership structure where "the boss has his net worth on the line with you." My view: alignment is good, but not owner-operator level.

Capital allocation must be split into three points. First, the dividend record is excellent. The company raised the dividend to $5.14 per share in 2025. In April 2026, it raised the quarterly dividend from $1.30 to $1.34, annualized at $5.36 per share, achieving 64 consecutive years of dividend increases. For a conservative long-term investor, this is one of JNJ's most valuable shareholder return traditions.

Second, R&D and acquisitions are necessary, but price discipline matters. In 2025, the company spent $14.67 billion on R&D. In the same year, it acquired Intra-Cellular and Halda for a combined net cash amount of about $17.5 billion. In 2024, it acquired Shockwave for about $11.5 billion of net cash. These deals have strategic logic: add neuroscience, add cardiovascular exposure, and add high-growth pipelines and platforms. But from an owner perspective, I would not automatically give a high score just because "the direction is right." The greatest danger in large pharmaceutical acquisitions is buying short-term growth at high valuations and exchanging cash and credit for future uncertainty. It is too early to make a final judgment on these transactions. For now, they have a strengthening logic, but returns still need time to prove themselves.

Third, buybacks do not especially excite me. The company repurchased about $5.95 billion of stock in 2025 and another about $4.0 billion in Q1 2026. But in Q1 2026, it also added about $7.2 billion of net new short- and long-term debt financing. In other words, while valuation was not cheap, the company partly used higher leverage to support shareholder returns and capital arrangements. For a company with extremely strong cash flow, this is certainly not dangerous. But for a "balanced and conservative" investor, it also shows that management is not fully following a Buffett-style discipline of repurchasing aggressively only when shares are clearly undervalued. I therefore can only score it 3/5, not higher.

Financial Quality and Owner Earnings

First, here is a concise historical financial table. A key caveat: 2021 to 2022 are on the pre-separation consolidated basis, while 2023 to 2025 are closer to the current two-segment basis. 2023 to 2025 are also affected by the Kenvue separation and talc accounting, so cross-period comparability is not perfectly clean. This table is better for assessing "cash flow resilience" and "rough capital intensity" than for mechanically extrapolating growth.

Year	Sales	Operating Cash Flow	Capital Expenditure	Free Cash Flow	Year-end Net Debt
2021	93.8	23.4	3.7	19.8	2.1
2022	80.0	21.2	4.0	17.2	17.4
2023	85.2	22.8	4.5	18.2	6.4
2024	88.8	24.3	4.4	19.8	12.1
2025	94.2	24.5	4.8	19.7	27.8

Free cash flow in the table uses the conservative definition of "operating cash flow minus capital expenditure," calculated by this report from company filings. 2021 to 2022 sales and cash flow come from the 2021/2022 annual reports. 2023 to 2025 come from the 2023/2025 annual reports and the 2025 annual report cash flow notes. Year-end net debt comes from management liquidity disclosures for each year/quarter.

This table says a lot: no matter how noisy the accounting statements become, JNJ's cash flow has remained very hard. From 2021 to 2025, free cash flow generally stayed in the $17.2 billion to $19.8 billion range, while capital expenditure intensity was roughly 4% to 5% of sales. In 2025, the company still generated $24.5 billion in operating cash flow. Even in Q1 2026, when operating cash flow was only $2.5 billion, management clearly stated that the main reason was seasonal working-capital absorption from higher receivables and inventory and lower payables and other liabilities, not a collapse in demand. For long-term owners, this kind of "cash temporarily tied up in working capital while business scale continues to grow" is completely different from "profit fraud causing cash to disappear."

Are profits real cash profits or accounting profits? My judgment: JNJ's profits are broadly real, but GAAP profit is materially distorted in the short term by major litigation reserves, reserve reversals, the Kenvue separation, and acquisition accounting. For example, in 2025 the company recognized about $7.0 billion of previously accrued talc reserve reversal, which clearly lifted the 2025 pretax margin. By contrast, 2024 was dragged down by talc charges and the debt-for-equity loss on the remaining Kenvue stake. Therefore, if you focus on one-year net margin or P/E, it is easy to be pessimistic in 2024 and excited in 2025, but neither reaction is sufficiently "owner-like." A more credible approach is to focus on cash flow, capital expenditure, net debt, and product renewal capability.

Revenue growth, margins, cash flow, and capital returns. The company disclosed 2025 global sales CAGRs of about 6.7% and 5.2% over five and ten years, respectively. 2025 sales grew 6.0% year over year, mainly driven by volume growth. Gross margin has generally stayed high in recent years. 2025 gross profit was about $63.9 billion, implying a gross margin of about 67.9%; the 2024 gross margin was about 69.1%; and 2023 was about 68.8%. On a rough basis, reported ROE and ROA in 2025 look very high, but I do not recommend treating those numbers as a "true quality conclusion," because they are heavily affected by the talc reserve reversal and post-separation equity structure. The sounder conclusion is: JNJ's capital returns are probably still excellent, but accounting noise in 2024 to 2025 is too large to draw conclusions from single-year ROE.

Is the balance sheet solid? Answer: still solid, but it has moved from a "net cash fortress" to a "high-quality company with manageable net debt." At the end of 2025, the company had about $19.7 billion of cash and cash equivalents, about $47.9 billion of debt, and about $27.8 billion of net debt. By the end of Q1 2026, cash, cash equivalents, and marketable securities totaled about $22.1 billion, debt was about $55.0 billion, and net debt was about $32.9 billion. This is still not dangerous leverage. The company also has a $10.0 billion 364-day credit facility and access to the commercial paper market. But for conservative investors, JNJ is no longer a company whose debt can be treated as almost negligible.

Interest coverage and survival capacity. Interest expense in 2025 was about $971 million, while pretax income was about 34.6% of sales. Even after considering accounting noise, interest coverage remains very ample. My rough calculation shows that 2023 to 2025 EBIT/interest expense was still roughly in the range of nearly 19x to 33x, indicating that short-term debt-servicing risk is not high. The real concern is not "will it fail to repay debt next year?" It is "will capital allocation over the next few years keep using debt for activities whose returns are not high enough?"

Changes in inventory, receivables, and payables. In Q1 2026, the company explicitly disclosed that operating cash flow was affected by increases in receivables and inventory and declines in payables and other liabilities. For a global healthcare company, this is usually a phase-specific working capital fluctuation and is not enough on its own to indicate financial manipulation. The company still generated $24.1 billion of sales, $15.96 billion of gross profit, and $2.5 billion of operating cash flow in the first quarter. So far, I have not seen a clear warning signal that "profits depend on stretching receivables while cash flow keeps diverging."

Owner Earnings analysis. Using a Buffett-style approach, JNJ's owner earnings should not be directly equated with 2025 GAAP net income of $26.8 billion, because that figure includes accounting items such as litigation reserve reversals. A more prudent starting point is operating cash flow of $24.5 billion. Under the most conservative approach, treating all capital expenditure of $4.8 billion as necessary maintenance capex gives a 2025 "owner earnings floor" of roughly $19.7 billion. Under a more realistic approach, treating only about 75% of capital expenditure as maintenance would put owner earnings around $20.5 billion to $21.0 billion. For conservatism, the valuation section below uses about $20.0 billion as the normalized Owner Earnings starting point. Based on the current market capitalization of about $573 billion, the market is valuing JNJ at about 28x conservative Owner Earnings.

My conclusion: JNJ is absolutely not a company with attractive accounting profit but poor cash flow. On the contrary, it has very strong real cash flow capacity. The only issue is that the market price assigned to this real cash flow today is no longer cheap.

Valuation, Margin of Safety, and Opportunity Cost

As of May 22, 2026, JNJ traded at about $234.34, with a market capitalization of about $573 billion and a trailing P/E of about 27.2x. In Q1 2026, the company raised full-year sales guidance to about $100.8 billion and gave an adjusted EPS midpoint of about $11.55. Based on that guidance, the current price implies a forward adjusted P/E of about 20.3x. This is why the market is still willing to assign JNJ a relatively high valuation. It sees "re-acceleration after the STELARA decline." But for long-term conservative investors, whether it can grow and whether it is worth buying at this price remain separate questions.

Method 1: Owner Earnings discount model. The following uses my own conservative model rather than copying sell-side assumptions. The starting Owner Earnings are $20.0 billion to $21.0 billion; the discount rate is 7.5% to 8.5%; and terminal growth is 2.0% to 3.0%. The model results are as follows:

Scenario	Starting Owner Earnings	Growth Over Next Ten Years	Discount Rate	Terminal Growth	Estimated Intrinsic Value
Conservative	$20.0 billion	2.5%	8.5%	2.0%	about $120/share
Neutral	$20.5 billion	4.0%	8.0%	2.5%	about $165/share
Optimistic	$21.0 billion	5.5%	7.5%	3.0%	about $230/share

These valuation results are derived in this report from management-disclosed 2025 cash flow, Q1 2026 net debt, Q1 2026 share count, and the current market price. They are not company guidance. The interpretation is straightforward: the current price is already close to the optimistic case. For an investor who wants to hold for more than 10 years and is "balanced but conservative," this usually does not satisfy the margin-of-safety principle. The relevant inputs come from 2025 operating cash flow, 2026Q1 net debt, 2026Q1 share count, and the current market price.

Method 2: Relative valuation. Among verifiable current market data, JNJ's trailing P/E of about 27.2x is slightly higher than Abbott at 24.5x and Medtronic at 22.0x, but lower than Merck at 34.5x and Stryker at 36.6x. AbbVie at 106x trailing P/E is distorted by low GAAP EPS. Considering JNJ's business mix, litigation noise, and patent cliffs, I think JNJ is currently in the " high quality but not cheap " zone rather than "obviously discounted." Because I have not manually recalculated the latest EV/EBITDA, PB, and P/FCF for each comparable company, this report does not force unverified third-party snapshot data into those metrics. I would rather leave this part blank than manufacture false precision.

Method 3: Asset or liquidation value. For a company like JNJ, liquidation value has limited relevance. At the end of 2025, total assets were about $199.2 billion, including net intangible assets of about $50.4 billion and goodwill of about $48.8 billion. Together, these were about $99.2 billion, close to half of total assets. This means that book value underestimates successful brands, patents, physician relationships, and platform value. It also means the company does not have a particularly thick "hard-asset floor." Buying JNJ is not buying a pile of cash and land. It is buying professional capability, regulatory assets, brands, and future cash flow. In other words, this is not a stock well suited to liquidation-value downside support.

Final valuation range and price framework. Combining the three methods, I give the following range, which is more useful for practical decision-making:

Conservative intrinsic value range: $120 to $150/share. This is the result of conservative Owner Earnings, low growth, and a higher discount rate.
Reasonable intrinsic value range: $150 to $190/share. This is what I consider a normal valuation range for a high-quality mature healthcare company after considering litigation and patent risks.
Optimistic intrinsic value range: $190 to $230/share. This requires new platforms to deliver, litigation to remain controlled, reinvestment to go smoothly, and the valuation premium to largely hold.
Current price relative to intrinsic value: roughly a 25% premium to the upper end of the neutral range, and already close to the upper end of the optimistic range.
Required margin of safety: for this kind of mature leader, I would prefer at least a 15% to 25% discount before feeling more comfortable.
Ideal buy price range: $160 to $185/share.
Acceptable hold price range: $185 to $220/share.
Clearly overvalued price range: above $230/share.

The ranges above are my conservative framework, not precise point forecasts. Their purpose is to separate "good company" from "good price." At today's $234, I am more inclined to classify JNJ as a good company, but not a good enough price.

Margin of safety conclusion. The most fragile assumption at the current price is not "will JNJ collapse?" It is that "the market assumes JNJ can smoothly cross the STELARA/OPSUMIT and other product cliffs, keep converting acquisitions and R&D into mid- to high-single-digit growth, and avoid expanding litigation liabilities." If any one of those does not go well, today's valuation is easy to compress. From an opportunity-cost perspective, JNJ's current free cash flow yield of about 3.4% and dividend yield of about 2.3% are both below the 10-year Treasury yield of 4.57% and the Aaa corporate bond yield of 5.64%. That means the main source of excess return for investors can only be future growth and maintenance of a long-term valuation premium, not current cash return. For conservative capital, this is not a particularly comfortable starting point.

Risks, Counterarguments, Checklist, and Final Judgment

Most important risks. For JNJ, what truly matters is not day-to-day volatility, but the following risks that may cause permanent capital loss. First is competition and patent risk. The biosimilar impact on STELARA has already occurred, and the company clearly expects sales pressure to continue. OPSUMIT is expected to face generic competition in 2026. DARZALEX remains extremely strong, but its importance is too high, and neither its core patent structure nor its royalty-sharing structure lasts forever. Second is regulatory and reimbursement risk. Policies such as Medicare Part D redesign and 340B have already affected multiple products. Third is litigation risk. As of the end of March 2026, the present value of the talc-related reserve was about $3.4 billion, but there were still about 75,000 claimants, and the litigation tail is not fully measurable. Fourth is capital allocation risk. If the company continues large buybacks during high-valuation periods and continues high-priced acquisitions, shareholders may own an excellent company but receive mediocre returns. Fifth is business restructuring risk. If the planned orthopedic separation is poorly executed, it could disrupt MedTech's current organizational and profit structure.

Strongest opposing view. If I were short, I would say this: JNJ is no longer a defensive stock that is both "stable and cheap." It is a repriced high-quality asset. The market is rewarding it for successfully crossing the STELARA impact, integrating Shockwave and Intra-Cellular successfully, sustaining two-segment synergy, and assuming that talc risk ultimately comes in below worst-case fears. But the bear would point out: first, the drug-side patent cliff has not ended and has only been temporarily covered by new products; second, the device side is stable, but growth may not be strong enough to support the current premium; third, continuing sizable buybacks while debt rises suggests management is not very "stingy" about the share price; fourth, the cash return currently received by shareholders is below risk-free and high-grade credit yields, which is unfriendly to new buyers. I think this opposing view is valid and deserves serious attention.

What facts would make me admit I was wrong. If the following facts occur, I would revisit or even overturn the current analytical framework: first, core growth platforms such as TREMFYA, DARZALEX, CARVYKTI, SPRAVATO, CAPLYTA, RYBREVANT/LAZCLUZE fail for two to three consecutive years to offset declines in mature products such as STELARA/OPSUMIT; second, talc reserves and cash outflows materially exceed current reserves and push net debt higher; third, the orthopedic separation fails to improve MedTech and instead clearly damages margin and organizational efficiency; fourth, operating cash flow and free cash flow fall below $17.0 billion for an extended period with no sign of recovery; fifth, management continues large-scale buybacks at elevated valuations or makes frequent high-priced acquisitions. If these facts appear, the original judgment of "excellent company but expensive price" may need to be upgraded to "business quality is also deteriorating."

Comparison with other opportunities. Compared with broad indices, my view is that JNJ has better business stability and defensive characteristics than the index, but the current odds may not be better than the index. Compared with the 10-year Treasury or Aaa corporate bonds, the point is clearer: at today's rate levels, JNJ's dividend yield and free cash flow yield are not superior, so investors must rely on future growth and valuation maintenance to win. In other words, buying JNJ is not collecting rent. It is a bet that a high-quality medical innovation platform will keep compounding. That remains attractive for existing holders, but new buyers need a better entry point.

Investment Checklist.

Checklist Item	Judgment
Can I understand this business?	Pass
Does it have long-term stable demand?	Pass
Does it have a durable moat?	Pass
Does it have pricing power?	Pass, but more as "innovation/mix pricing power"
Can it generate stable free cash flow?	Pass
Are its capital returns excellent?	Pass, but accounting metrics are noisy
Is management trustworthy?	Pass
Is capital allocation rational?	Not fully pass
Is the balance sheet solid?	Pass
Is valuation below intrinsic value?	Fail
Is the margin of safety sufficient?	Fail
Would I be comfortable holding long term?	Pass, provided the purchase price is reasonable
What key facts would make me sell?	Product cliff out of control, litigation expansion, cash flow deterioration, capital allocation imbalance
Am I only tempted to buy because of share-price gains or market sentiment?	This impulse should be watched

The core meaning of this checklist is simple: JNJ's main problem is price, not business fundamentals.

Open questions / limitations. To avoid using unverified third-party snapshot data, this report does not force a full peer comparison of PB, EV/EBITDA, and P/FCF. In addition, because of the Kenvue separation and talc accounting, several GAAP margin and ROE metrics from 2023 to 2025 contain comparability noise. These gaps do not change the main conclusion, but they do affect the model's precision.

Final investment conclusion.

【Final Rating】 Watch

【One-sentence Investment Thesis】 JNJ remains a high-quality, understandable healthcare leader that can produce real cash flow for a long time, but buying at the current price offers insufficient margin of safety and mostly means paying a high price for quality and certainty.

【Core Bull Case】 The business structure is clear, with Innovative Medicine + MedTech as dual engines and long-term stable demand. Free cash flow capacity is very strong, staying broadly stable in the $17.0 billion to $20.0 billion range from 2021 to 2025. The moat is real, coming from patents, registration, scale, global channels, physician switching costs, and brand. The company has strong renewal capability: new products contributed about 25% of sales in 2025, and 2025 R&D spending was about $14.7 billion. The dividend culture is extremely strong, with 64 consecutive years of dividend increases achieved in 2026.

【Core Bear Case】 The current valuation is not cheap, and the margin of safety is insufficient under conservative to neutral valuation assumptions. Product cliffs and competitive pressure around STELARA, OPSUMIT, and eventually DARZALEX are real. Talc litigation has not truly ended, and reserves carry tail uncertainty. Net debt has risen noticeably over the past two years, while the company has still conducted sizable buybacks when valuation was not low. Whether large acquisitions truly create per-share value still needs time to prove.

【Key Assumptions】 New growth platforms can continue to offset declines in mature products. Talc-related cash outflows will not materially exceed current reserves. Future management capital allocation will place more weight on per-share value than scale. If the MedTech orthopedic separation proceeds, it will not damage the overall profit structure.

【Fair Buy Price】 $160 to $185/share. The basis is that this range corresponds more closely to a conservative owner earnings yield of 4.5% to 5.0% and sits closer to the safety zone under my neutral valuation framework.

【Target Holding Period】 More than 10 years. This is not a short-term trading target. If investing from an owner perspective, one should at least cross a full product iteration and capital allocation cycle.

【Expected Annualized Return】 The following are rough inferences based on the current price, not precise forecasts: Conservative case: -2% to 1%/year. Neutral case: 1% to 4%/year. Optimistic case: 4% to 7%/year. These ranges come from the current free cash flow yield of about 3.4%, future growth assumptions, and possible valuation contraction or maintenance.

【Maximum Loss Risk】 If litigation expands, growth platforms stall, capital allocation becomes imbalanced, and the market rerates the stock down to a more ordinary large-cap healthcare blue-chip range, a medium- to long-term share-price drawdown of 40% to 50% is not unimaginable. This is not the most likely scenario, but conservative investors must accept the possibility in advance.

【Tracking Indicators】 Going forward, I will continue to track: STELARA decline rate, TREMFYA growth quality, DARZALEX growth and patent progress, CARVYKTI capacity and penetration, SPRAVATO/CAPLYTA ramp, MedTech cardiovascular and Vision growth, operating cash flow and free cash flow, net debt level, talc cash outflows and reserve changes, orthopedic separation progress and profit impact.

【Signals Triggering Reassessment】 Growth platforms clearly stall for several consecutive quarters. Litigation reserves are revised materially upward. Free cash flow falls below about $17.0 billion for multiple consecutive years. The company continues to support large buybacks with higher leverage. The orthopedic separation or large acquisitions clearly worsen margins and cash flow.

【Final Recommendation】 If you already own JNJ and your cost basis is reasonable, I lean toward "hold and continue tracking," rather than immediately selling an excellent company simply because short-term valuation is elevated. If you are considering a new purchase today, my suggestion is restraint: keep it on a high-priority watchlist and wait for a better price or clearer proof of reinvestment execution. From the perspective of a long-term business owner, JNJ still deserves respect. From today's odds, it is not compelling enough.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.

Baillie Framework · Ten Questions for Growth Investing

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

How high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

The ceiling is high, but this is a case of “continuing to deepen inside a huge existing pie,” not creating a brand-new market from scratch. That is exactly what gives JNJ its growth profile: steady compounding rather than explosive exponential growth.

Start with scale. JNJ’s 2025 total sales were about 94.2 billion dollars, including about 60.4 billion dollars from Innovative Medicine and about 33.8 billion dollars from MedTech. The global prescription drug + medical device markets it operates in are measured in “trillions of dollars.” Aging populations, chronic disease, oncology, cardiovascular procedures, and vision correction are long-term underlying needs that are rising and almost irreversible. The report characterizes the industry as having “stable demand, innovation-driven growth, heavy regulation, capital intensity, and concentrated profit pools,” and gives industry attractiveness a 4/5. This is a large pie that is still expanding, but JNJ has long been inside it.

The key point is that almost all of JNJ’s growth comes from “taking share, raising penetration, and launching next-generation products in already existing disease areas,” rather than opening demand that previously did not exist. The report’s own breakdown is candid: in 2025 sales growth, volume contributed about 8.4%, price contributed about -3.1%, and the main driver was “selling more drugs, more devices, and more consumables,” not inventing a completely new category. Even frontier innovations such as CARVYKTI (CAR-T cell therapy) and RYBREVANT/LAZCLUZE are still essentially competing for better efficacy and earlier lines of therapy in established markets such as “multiple myeloma” and “lung cancer,” where the diseases are already defined and competitors already exist. In Baillie Gifford terms, this is “expanding an existing pie.”

Measured by Baillie Gifford’s LTGG yardstick of “finding great growth stocks that can rise fivefold in ten years,” JNJ does not score highly on this question. It has no shortage of ceiling; what it lacks is the explosive narrative of “creating a new market.” It is more like a compounding machine that keeps taking share in trillion-dollar arenas, not a disruptor that can pull TAM (total addressable market) from zero to the skyline. The report discloses that “more than 75% of sales come from categories ranked No. 1 or No. 2 globally by market share,” and that it already has “28 platforms with annual sales above 1 billion dollars.” That shows exactly that it is already a leader inside an existing pie. The advantage of a leader is stability; the cost is that multiplying several times from here requires overall market expansion + continuous incremental innovation, not a single ignition point. Conclusion: the market ceiling is high and real, but it belongs to “deepening an existing large pie,” which is the natural upper bound on JNJ’s growth quality.

Jun 10, 2026
Can its revenue at least double over the next five years? Is growth mainly driven by volume, price, or new businesses?3/10

The conclusion is straightforward: revenue is highly unlikely to double over the next five years. A more realistic outcome is “mid- to high-single-digit compound growth.” The main drivers are “volume” and “new products/new platforms,” while price is not a tailwind and is instead a drag. On the Baillie Gifford yardstick, JNJ is clearly weak on this question.

Use the company’s own figures first. 2025 total sales were about 94.2 billion dollars. In Q1 2026, the company raised its full-year 2026 sales guidance to about 100.8 billion dollars (midpoint about +7.0%). The report also discloses that global sales CAGR over the past five years and ten years was about 6.7% and 5.2%, respectively. Doubling revenue within five years requires sustained compound growth of about 15%/year. That is almost 2-3 times JNJ’s historical growth rate, and it is unrealistic for a giant with nearly 100 billion dollars in revenue that is also facing patent cliffs. Even under an optimistic case, five-year revenue is more likely to land around 130-140 billion dollars (about 7%-8% compound), far short of the roughly 190 billion dollars needed to double.

The driver mix is also very clear in the report: in 2025 growth, volume was about +8.4%, price about -3.1%, and FX about +0.7%. In other words, real growth almost entirely came from “selling more,” while price was a net drag. This differs from the consumer goods or software growth pattern of “rising volume and price together”: the pharmaceutical side faces reimbursement constraints, the Medicare Part D redesign, 340B, and other policy price pressure; the device side faces hospital cost controls and volume-based procurement. Pricing power is “implicit,” attached to the premium of next-generation products, rather than the ability to simply raise the price list.

So who carries growth? “New businesses/new platforms” must offset the “old-product cliffs.” New products contributed about 25% of sales in 2025, which is what separates JNJ from drug companies merely living off legacy products. Growth engines are concentrated in TREMFYA, DARZALEX (2025 global net sales about 14.3 billion dollars), CARVYKTI, RYBREVANT/LAZCLUZE, SPRAVATO, CAPLYTA, and others. At the same time, however, the impact of biosimilars on STELARA created about a 1040-basis-point drag on the 2025 Immunology segment, and OPSUMIT faces generic competition in 2026. Put differently, JNJ’s growth over the next five years is essentially a race between “new platform ramp-up vs mature product decline.” The net result is mid- to high-single digits: steady, but nowhere near the explosive “five-year doubling” Baillie Gifford wants.

Jun 10, 2026
Five years from now, what will take over as the next growth engine? Does this “second curve” exist today?5/10

JNJ’s “second curve” does exist today, and there is more than one. Its defining feature, however, is rolling succession through “portfolio renewal,” not a single disruptive new engine. This is where JNJ differs most from a typical Baillie Gifford growth stock: it does not rely on one stunning curve, but on a basket of platforms taking turns to fill the gaps.

Look at the succession lineup. In Immunology, TREMFYA is taking over the gap left by STELARA’s biosimilar-driven decline (STELARA created about a 1040-basis-point drag on the 2025 Immunology segment). In Oncology, DARZALEX (2025 global net sales about 14.3 billion dollars), CARVYKTI (CAR-T cell therapy), and RYBREVANT/LAZCLUZE (lung cancer) are the main upswings. In Neuroscience, SPRAVATO and the newly acquired CAPLYTA (from the Intra-Cellular acquisition) are emerging forces. The device-side second curves are also clear: Shockwave (intravascular lithotripsy), Abiomed (heart pumps), electrophysiology, and ophthalmology products such as ACUVUE contact lenses and the VELYS surgical robot are all high-growth platforms. The report summarizes this mechanism accurately: “the old moat narrows, and the new moat must connect.”

The hard evidence that the “second curve truly exists” is JNJ’s R&D and pipeline reproduction capability: 2025 R&D spending was about 14.7 billion dollars (about 15.6% of sales), and that year it received 51 approvals, submitted 32 filings, and initiated 11 new Phase 3 programs; new products (launched over the past five years) already contributed about 25% of 2025 sales. This shows succession is not a vision on a PPT deck, but a reality already visible in the income statement. In Q1 2026, the company raised its 2026 sales guidance to about 100.8 billion dollars. The market is willing to keep paying a premium precisely because it is looking at “re-acceleration after STELARA’s decline.”

But viewed honestly through a Baillie Gifford lens, these second curves are “gap-filling,” not “company-recreating.” Their first job is to cover the decline from STELARA, OPSUMIT, and even DARZALEX after its post-2029 patent expiry (Genmab is entitled to a sales royalty of up to about 20%); net growth comes second. This is not like the “next iPhone” that can redefine the company’s scale. So the conclusion is: the second curves are genuinely present today and already validated, which underpins JNJ’s defensive compounding; but they form a steady state of “a basket of rolling handoffs,” lacking the nonlinear imagination Baillie Gifford loves, where one curve can carry the company to fivefold growth.

Jun 10, 2026
What is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

JNJ’s core moat is a composite of “patents and regulatory barriers + global channel scale + doctor-side switching costs.” It is real and deep. But over the next three to five years, the direction is not one-way widening; it is “stable overall, locally narrowing on the pharmaceutical side, and locally widening on the device side.” The report gives the moat a 4/5, and I agree with that relatively stable assessment.

Start with the true sources of the moat. The hardest first-layer moat is patents, clinical data, regulatory dossiers, and approvals: in 2025, the company received 51 approvals, submitted 32 filings, and initiated 11 new Phase 3 programs. That is the “reproduction” process of the moat, not a one-off asset. Scale is also prominent: 2025 sales were about 94.2 billion dollars, spanning pharmaceuticals and devices. The report discloses that “more than 75% of sales come from categories ranked No. 1 or No. 2 globally by market share,” and that it already has “28 platforms with annual sales above 1 billion dollars.” Switching costs are especially strong on the device side. Once surgical, orthopedics, and electrophysiology products enter hospital workflows and physician training systems (such as the ATTUNE orthopedic platform and VELYS robot), replacement costs are high. One “no” must be stated clearly: network effects. JNJ is not a platform company; its moat comes from science/regulation/channels/brand, not user-to-user network effects. The report directly marks this as “no,” which is honest, not a flaw.

But the moat is evolving across “time states,” and that is the key to answering this question. The pharmaceutical side is locally narrowing: STELARA has entered the biosimilar impact period (a drag of about 1040 basis points on the Immunology segment in 2025), OPSUMIT faces generic competition in 2026, and DARZALEX (about 14.3 billion dollars in 2025, about 15% of total revenue) has core U.S. patents that broadly run to 2029, while JNJ also has to pay Genmab a sales royalty of up to about 20%. Patents are time-limited moats. That is the structural erosion the pharmaceutical side cannot avoid. The device side is locally widening: high-growth platforms such as Shockwave, Abiomed, electrophysiology, and ophthalmology, combined with physician training and procedure penetration, are increasing path dependence and thickening the moat.

Using Baillie Gifford’s discipline of “viewing moats across time states,” the closing point is this: historical indicators (high gross margin, high market share) only prove that the moat “used to be” strong. What really needs watching is the marginal change over the next 4-8 quarters: whether new platforms can connect faster and wider than the old moats around STELARA/OPSUMIT/DARZALEX narrow. The report’s judgment is a “portfolio-renewal moat,” stable overall. I think this 4/5 is fair: JNJ’s moat will not collapse, but it is also not the kind of expanding moat that keeps widening and pulling farther away from competitors. That is exactly why it deserves pricing as a “high-quality defensive compounder,” not a “cheap growth” valuation.

Jun 10, 2026
If its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?6/10

JNJ’s “reinvention DNA” is one of its most underestimated long-term assets. As a company with more than 130 years of history, it has repeatedly crossed product cycles through “portfolio restructuring + proactive pruning.” Its handling of mistakes and bad news is generally “adequate provisioning, no concealment, but a conservative tempo.” On the Baillie Gifford yardstick, JNJ is above average on this question.

Start with the evidence chain for reinvention. This is the implied precondition behind the question of “whether it can be reborn if the core business is disrupted.” JNJ’s history itself is a record of continuous reinvention: in 2023, it completed the separation of the consumer health business Kenvue, narrowing itself from a three-pillar giant of “pharmaceuticals + devices + consumer” into a dual engine of “Innovative Medicine + MedTech,” proactively cutting lower-growth assets and focusing on higher R&D-return areas. The report notes that while it was “handling the Kenvue separation, litigation, and patent pressure,” it also completed transactions such as Shockwave, Intra-Cellular, and Halda, while maintaining about 24.5 billion dollars of operating cash flow in 2025. This ability to “deal with old problems with one hand and build new platforms with the other” is organizational-level reinvention muscle. A more forward-looking signal is that the company is planning to separate the Orthopedics business from MedTech (target mid-2027), raising the share of high-growth assets in the MedTech portfolio from about 50% to above 70%. It is willing to “break itself apart” again to improve portfolio quality.

Then look at the real stress test of “core business disruption”: STELARA’s biosimilar impact is one live case. In 2025, STELARA created about a 1040-basis-point drag on the Immunology segment, yet companywide sales still grew 6.0% to about 94.2 billion dollars, offset by new platforms such as TREMFYA. The portfolio resilience is real, not a slogan. It shows that when a single pillar is “disrupted,” JNJ has genuine skill in cushioning the blow through a portfolio response.

As for “how it handles mistakes and bad news,” the sharpest example is the talc litigation. JNJ’s approach has been to keep provisioning rather than avoid the issue: as of Q1 2026, the present value of talc-related reserves was about 3.4 billion dollars; in 2025, it also reversed about 7.0 billion dollars of reserves previously recorded for the bankruptcy plan (because the bankruptcy path was blocked). These two movements show that management puts bad news on the table in accounting terms and adjusts with developments, rather than hiding it. But the weakness should be stated honestly: critics would say JNJ tried to isolate talc liabilities through the “Texas two-step” bankruptcy strategy and was rejected by courts multiple times. That reflects a tendency to “use legal maneuvering first, then settle pragmatically” when handling bad news; the rhythm is not always the most forthright.

Overall judgment: JNJ’s reinvention DNA (separations, acquisitions, portfolio restructuring) has been validated across multiple cycles and is genuinely strong. Its provisioning for mistakes and bad news is generally adequate and disclosure is transparent, but in major litigation it prefers “conservative maneuvering + eventual pragmatism” over immediate full closure. From a Baillie Gifford perspective, this is an organization that “does not die easily and can renew its blood.” Reinvention capability is the foundation that lets it cross product cliffs.

Jun 10, 2026
Does management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for five to ten years from now?5/10

The conclusion has two layers: long-term view: yes, JNJ’s management does show a cross-cycle mindset and a willingness to bet on the future; deep alignment of interests: no, this is not an owner-style team where “the boss has put his own net worth on the line with you.” JNJ cannot get a high score on this question, which Baillie Gifford weights heavily, because it lacks the strongest long-term alignment signal: “founder/controlling shareholder with a large stake.”

First, why the long-term view is “yes.” The evidence that JNJ is willing to sacrifice current profit for five to ten years from now is hard: 2025 R&D spending was about 14.7 billion dollars (about 15.6% of sales), and it initiated 11 new Phase 3 clinical programs that year. These are long-term investments where the company “spends money now and may only be repaid years later.” It also makes proactive structural choices: the 2023 separation of the consumer health business Kenvue, and the planned mid-2027 separation of Orthopedics from MedTech, are decisions to improve portfolio quality at the cost of short-term scale and profit. The dividend discipline best reflects its long-term tradition: in April 2026, the company raised its quarterly dividend to 1.34 dollars, or 5.36 dollars/share annualized, marking 64 consecutive years of dividend increases. That continuity across decades and multiple CEOs is clear evidence that “long-termism has been institutionalized.”

But “deep alignment of interests” must honestly be discounted. This question specifically mentions “especially the founder,” and JNJ has long had neither a founder nor a controlling family. It is a century-old blue chip with highly dispersed ownership. According to the report, based on the 2026 proxy statement, all directors and executives together still owned/controlled less than 1% of outstanding shares; CEO Joaquin Duato beneficially owned about 1.408 million shares. The company also has mandatory stock ownership requirements of 12 times annual salary for the CEO and 6 times annual salary for other executives, prohibits pledging/hedging/short selling, and has a clawback policy. These governance designs “are all in place,” and interest alignment is good. But this is the “professional manager + standard governance” model, not Baillie Gifford’s preferred owner-operator structure where “a founder has most of his net worth in the company and is in the same boat as minority shareholders.” Duato’s 1.408 million shares are tiny relative to a market value of about 569-574 billion dollars (June 2026, share price about 237 dollars).

One more reality deserves a deduction: capital allocation discipline is imperfect. The report notes that in Q1 2026, net debt had risen to about 33.0 billion dollars, while the company still repurchased about 4.0 billion dollars of stock and added about 7.2 billion dollars of net debt. Using higher leverage to support buybacks when the valuation is not cheap shows management has not strictly followed the discipline of “repurchasing aggressively only when the stock is clearly undervalued.” The report gives capital allocation a 3/5, and I agree.

Overall: management deserves “cautious approval.” The long-term view is real, governance is standard, and the dividend culture is excellent; but alignment remains at the level of “good professional-manager alignment,” far from founder-level deep same-boat ownership. With flaws in capital allocation discipline as well, JNJ is only middling on a question that carries high weight in the Baillie Gifford framework.

Jun 10, 2026
If it disappeared tomorrow, how much would customers miss it? Is its growth method sustainable and not dependent on harming society or regulation?6/10

Answer in two dimensions: indispensability: very high. If JNJ disappeared tomorrow, patients, doctors, and hospitals would miss it immediately and intensely. Growth sustainability and social/regulatory compatibility: generally sustainable and broadly positive, but the talc litigation is a thorn in its “social compatibility.” Overall, JNJ is strong on this question, but not perfect.

Start with “how much would they miss it.” Many JNJ products sit in the category of “essential treatment.” Substitutability is low, and supply interruption would have serious consequences. In oncology, DARZALEX (2025 global net sales about 14.3 billion dollars) is a core therapy for multiple myeloma, and CARVYKTI is a CAR-T cell therapy. These are life-extending treatments, not optional consumer goods. On the device side, if surgical tools, orthopedic joints (ATTUNE), electrophysiology products, and heart pumps (Abiomed) were pulled from operating rooms, hospital procedure workflows would directly stall. The report notes that the company has “more than 75% of sales from categories ranked No. 1 or No. 2 globally by market share” and covers both pharmaceuticals and devices. This deep embedding in the healthcare system is exactly the “customers cannot live without you” quality this Baillie Gifford question is seeking. Put differently, JNJ’s disappearance would cause “treatment interruption,” not merely “inconvenience,” so the intensity of being missed is in the highest tier.

But it is important to distinguish honestly between “the company is indispensable” and “a single product is indispensable.” The pharmaceutical side has patent terms. STELARA has already been replaced by biosimilars, OPSUMIT faces generics in 2026, and DARZALEX’s core U.S. patents broadly run to 2029. Once patents expire, generics/biosimilars can provide equivalent efficacy at lower prices. That means JNJ’s indispensability is tied more to “continuously innovating the next generation of products” than to permanent monopoly over any single molecule. This connects the question directly to the moat question: customers miss you because you keep producing better new things, not because others can never make the old things.

Now consider the implied premise of “whether growth is sustainable and whether it depends on harming society and regulation.” On the positive side, JNJ’s growth has a healthy underlying character: in 2025 growth, volume contributed about +8.4% and price about -3.1%. Growth came from “treating more disease and performing more procedures,” not from broad price hikes that squeeze payers, which is a positive for social compatibility. It is also creating real clinical value continuously (it received 51 approvals in 2025). On the regulatory side, the company has standard governance, transparent disclosure, and long-term compliance relationships with FDA/EMA, which itself forms part of the moat.

But the talc litigation is an unavoidable stain on social/regulatory sustainability: as of Q1 2026, the present value of related reserves was about 3.4 billion dollars. The report notes that there were still about 75,000 U.S. claimants and that tail losses were not fully capped. This kind of large-scale tort litigation around “whether a historical product caused cancer” is a substantive test of corporate social compatibility, and it is a risk new buyers must keep watching for a long time. Overall judgment: indispensability is extremely high, and the growth method is generally healthy and does not depend on harming society; but the talc thorn prevents an unreserved full score on “social/regulatory sustainability.”

Jun 10, 2026
How are the unit economics of this business, such as gross margin and incremental returns? Does scale make it better or worse? Where does the money it earns go?7/10

The unit economics are excellent: about 68% gross margin, strong and real free cash flow, and meaningful scale effects. Scale makes it better, not worse. This is one of JNJ’s strengths. As for “where the money it earns goes,” the answer is four parallel tracks: dividends + R&D + acquisitions + buybacks. Dividends are the strongest; buybacks are the most questioned.

Start with the hard data on unit economics. 2025 gross profit was about 63.9 billion dollars, with gross margin of about 67.9%, broadly stable at a high level in recent years (about 69.1% in 2024 and about 68.8% in 2023). More important is cash conversion: 2025 operating cash flow was about 24.5 billion dollars, and free cash flow was about 19.7 billion dollars. The report records that free cash flow remained stable at about 17.2-19.8 billion dollars over 2021-2025, and capex intensity was only about 4%-5% of sales. This shows JNJ is not a company with “pretty accounting profit but poor cash,” but one with genuinely strong cash earnings. The report specifically notes that 2025 GAAP net income of 26.8 billion dollars included an accounting disturbance from the reversal of about 7.0 billion dollars of talc reserves, so the safer “owner earnings” starting point is 24.5 billion dollars of operating cash flow, normalized to about 20.0 billion dollars.

Next, consider the direction of scale and incremental returns. JNJ’s scale effects are real: 2025 sales were about 94.2 billion dollars, spanning pharmaceuticals and devices. R&D platforms, regulatory compliance systems, and global commercial channels can all be reused across products. The report notes that the company can absorb failed projects, roll products out globally faster, and spread fixed compliance and sales costs, and that “this scale and reuse capability itself is part of the cost advantage.” Scale also provides portfolio resilience: in 2025, STELARA dragged the Immunology segment by about 1040 basis points, yet companywide sales still grew 6.0%. So getting larger makes the business “better”: it amplifies the leverage of innovation platforms and smooths single-product volatility. The honest marginal constraint is that the pharmaceutical side faces Medicare price pressure, 340B, and other policies, with price contribution negative (about -3.1% in 2025). Incremental returns therefore come from “volume + new products,” not price increases, which is the natural ceiling on healthcare unit economics.

Finally, look at “where the money it earns goes,” which is central to Baillie Gifford’s assessment of capital allocation quality. There are four tracks. First, dividends: in 2026, the annualized dividend rose to 5.36 dollars/share, with 64 consecutive years of growth, its most valuable tradition. Second, R&D: about 14.7 billion dollars in 2025, a necessary investment in moat reproduction. Third, acquisitions: in 2025 it acquired Intra-Cellular and Halda for about 17.5 billion dollars of net cash, and in 2024 acquired Shockwave for about 11.5 billion dollars. The direction (adding neuroscience, cardiovascular, and pipeline assets) is right, but “whether it bought the right things at good prices” still needs verification. Fourth, buybacks: about 5.95 billion dollars in 2025 and another about 4.0 billion dollars in Q1 2026, while net debt increased by about 7.2 billion dollars over the same period and net debt rose to about 33.0 billion dollars. Leveraged buybacks when valuation is not cheap dragged down what was otherwise a very attractive unit-economics story. The report gives capital allocation a 3/5, and this is the weak point. Overall: unit economics quality is high and scale effects are positive, but whether “the money is spent smartly enough” deserves a question mark.

Jun 10, 2026
What conditions would need to hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today’s share price?2/10

Plainly: the conditions for JNJ to rise fivefold in ten years, let alone more, are almost impossible to satisfy simultaneously. Today’s share price embeds not “growth,” but “quality premium + cash-flow certainty.” This is JNJ’s most fatal weakness under the Baillie Gifford framework. It is not essentially an LTGG stock.

Lay out “what conditions must hold simultaneously for a fivefold rise in ten years.” Starting from a market value of about 569-574 billion dollars (June 2026, share price about 237 dollars), fivefold implies a market value of about 2.8-2.9 trillion dollars ten years later. To get there, the following conditions must hold “simultaneously”: (1) revenue grows from about 94.2 billion dollars to the 300-400 billion dollar range, implying sustained compound growth of about 13%-17%/year, which is 2-3 times the historical growth rate (past five-/ten-year CAGR about 6.7%/5.2%); (2) the patent cliffs of STELARA, OPSUMIT, post-2029 DARZALEX (about 14.3 billion dollars in 2025), and others are not only fully filled by new platforms, but exceeded by large net additions; (3) valuation multiples do not contract and perhaps even expand; (4) talc litigation does not expand the balance sheet, and the regulatory/payment environment does not apply further price pressure. For a healthcare giant with nearly 100 billion dollars of revenue, negative price contribution (about -3.1% in 2025), and ongoing patent cliffs, the combined probability of this set of conditions is extremely low. The report’s intrinsic value model supports this too: even in the optimistic scenario (starting owner earnings of 21.0 billion dollars, ten-year growth of 5.5%, discount rate of 7.5%), intrinsic value is only about 230 dollars/share, in line with the current price, with no sign of a fivefold outcome.

Now consider “what expectations today’s share price embeds.” As of the report cutoff date (May 22, 2026), JNJ’s share price was about 234.34 dollars and trailing-twelve-month P/E about 27.2 times. Based on the raised Q1 2026 guidance of 2026 full-year sales of about 100.8 billion dollars and adjusted EPS guidance of about 11.55 dollars, the current price implies a forward adjusted PE of about 20.3 times. The market is pricing a mid- to high-single-digit growth company at about 20 times forward earnings and about 27 times TTM earnings. The embedded expectation is not “explosion,” but “smooth re-acceleration to mid- to high-single-digit growth after STELARA’s decline + persistence of a quality premium + controllable litigation.” In other words, today’s price has largely priced in “a high-quality leader crossing the product cliff successfully.” The report therefore classifies the current price as “near the upper end of my optimistic scenario,” about a 25% premium to the neutral range (150-190 dollars).

The opportunity-cost perspective is even more direct: JNJ’s current free-cash-flow yield is only about 3.4%, and its dividend yield about 2.3%, both below the 10-year Treasury yield of about 4.5% and Moody's Aaa corporate bond yield of about 5.5%. In other words, the immediate cash return for a new buyer does not even beat the risk-free rate; all excess return must come from betting on “future growth + maintained valuation.” Conclusion: the conditions for a fivefold rise in ten years are unrealistic, and today’s share price embeds “paying a high price for certainty,” not “leaving odds for growth.” On the Baillie Gifford yardstick, this is a question JNJ is bound to lose.

Jun 10, 2026
Why has the market not realized all this yet? Is it that investors do not understand it, look down on it, or cannot look far enough? What will become the “narrative inflection point”?3/10

For JNJ, this question should be asked in reverse: the market has not “failed to realize” it. Quite the opposite, JNJ is an extremely thoroughly researched mega-cap blue chip with almost no cognitive gap. So Baillie Gifford’s usual three-way split of “do not understand / look down on / cannot look far enough” points here not to “the market underestimates it,” but to “the market has priced it quite fully, perhaps even richly.”

Start with why there is almost no “cognitive gap” here. JNJ is a Dow component and one of the world’s most heavily covered healthcare leaders, with a market value of about 569-574 billion dollars (June 2026, share price about 237 dollars). Sell-side analysts, reimbursement data, patent expiry schedules, and litigation developments are all public and repeatedly modeled. This is not the kind of “small, neglected, hard-to-understand new species” that Baillie Gifford prefers. It is a stock “everyone understands and everyone watches.” The report characterizes the current price as “high quality but not cheap” and “near the upper end of the optimistic scenario,” with about a 25% premium to the neutral range (150-190 dollars). That is a sign of “full pricing or even slight expensiveness,” not “hidden value waiting to be discovered.”

Now test the three ideas of “do not understand / look down on / cannot look far enough” one by one for JNJ:

“Do not understand” — not valid. JNJ’s business model is clear (selling drugs + selling devices + selling consumables). The report gives “can this business be understood” a 4/5, and the enterprise-level model is entirely understandable. The difficulty lies only in molecular-level science and regulatory complexity, which is not a cognitive barrier for professional healthcare investors.

“Look down on” — partly valid, but in the opposite direction. The market does apply a discount for JNJ’s “old-drug cliffs” and “talc litigation”: STELARA faces biosimilar impact (about a 1040-basis-point drag on the Immunology segment in 2025), while the present value of talc reserves is about 3.4 billion dollars and the tail is not fully capped. These issues suppress valuation. But this “looking down on it” is a justified discount, not a mispricing; the report itself says the bear case is “valid and worth taking seriously.”

“Cannot look far enough” — this is the only place where a slight cognitive gap may exist, but the direction is ambiguous. The market may be underestimating the durability of new-platform handoffs (TREMFYA, DARZALEX at about 14.3 billion dollars in 2025, CARVYKTI, Shockwave). In Q1 2026, the company raised sales guidance to about 100.8 billion dollars, and the market has already started paying for “re-acceleration after STELARA’s decline” (forward adjusted PE about 20.3 times). But that is exactly why the optimistic “long view” is already partly priced in, leaving new buyers with thin odds.

Finally, answer the implied question: “what will become the narrative inflection point.” For a stock like JNJ that is already fully priced, inflection is more likely downward than upward: (1) an unexpected expansion of talc litigation and a major reserve increase would break the “controllable risk” narrative; (2) if new growth platforms visibly slow for two or three consecutive quarters and fail to cover the decline of STELARA/OPSUMIT/future DARZALEX, the core assumption of “smoothly crossing the product cliff” would be punctured; (3) if management keeps using leveraged buybacks during high-valuation periods (Q1 2026 net debt already about 33.0 billion dollars), per-share value would erode; (4) conversely, an upward inflection would require the Orthopedics separation to materially improve MedTech margins, or a new platform to ramp far above expectations. Overall judgment: JNJ does not fit the narrative of a “great growth stock the market cannot see.” It is a high-quality defensive asset that “the market sees very clearly and has already priced richly.” The real inflection risk tilts downward, which is the opposite of the cognitive-gap-driven nonlinear upside Baillie Gifford seeks.

Jun 10, 2026

Ask about this report

Members can ask about this report; once answered it appears under "Reader Q&A" on this page. You can also highlight a passage in the text to ask about it directly.